2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
暂无分享,去创建一个
[1] C. Reid,et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.
[2] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[3] T. Lumley,et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. , 2002, Archives of internal medicine.
[4] A. Zanchetti,et al. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? , 2002, Journal of hypertension.
[5] J. Flack. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. , 2002, Current hypertension reports.
[6] Steven Snapinn,et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.
[7] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[8] G. Mancia,et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. , 2002, Archives of internal medicine.
[9] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[10] H. Vorster,et al. The emergence of cardiovascular disease during urbanisation of Africans , 2002, Public Health Nutrition.
[11] M. Cooper,et al. Combination antihypertensive therapy in the treatment of diabetic nephropathy. , 2002, Diabetes technology & therapeutics.
[12] S. Yusuf,et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.
[13] D. Levy,et al. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease , 2001 .
[14] Jiang He,et al. Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2001, Hypertension.
[15] N. Poulter,et al. Improved Hypertension Management and Control: Results From the Health Survey for England 1998 , 2001, Hypertension.
[16] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[17] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[18] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[19] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[20] H. Pham,et al. Opportunities for improving the quality of hypertension care in a managed care setting. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[21] R. Devereux,et al. Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PR , 2001, Circulation.
[22] R. Schrier,et al. The Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Pooled Analysis of Individual-Patient Data from 11 Randomized, Controlled Trials , 2001, Annals of Internal Medicine.
[23] G. Khor,et al. Cardiovascular epidemiology in the Asia-Pacific region. , 2001, Asia Pacific journal of clinical nutrition.
[24] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[25] R. Collins,et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial , 2001, Journal of hypertension.
[26] S. Oparil,et al. Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood Pressure lowering Drugs , 2001, Current hypertension reports.
[27] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[28] Kukin Ml. The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.
[29] N. Milas,et al. Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.
[30] W A Bartlett,et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients , 2001, Heart.
[31] G. Bray,et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. , 2001, The New England journal of medicine.
[32] C. Roehrborn,et al. Benign prostatic hyperplasia. , 2020, BMJ.
[33] P. Whelton,et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.
[34] C. Schmid,et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.
[35] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[36] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[37] K. Bandeen-Roche,et al. Appendix 1 , 2019, European Journal of Human Genetics.
[38] B Neal,et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.
[39] B. Tomlinson,et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention , 2000, Journal of Human Hypertension.
[40] D. Vidt,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone , 2000 .
[41] Michael D. Brown,et al. The Role of Exercise Training in the Treatment of Hypertension , 2000, Sports medicine.
[42] J. Froom,et al. The urgent need to improve hypertension care. , 2000, Archives of family medicine.
[43] P. Sareli,et al. Antihypertensive Effect of Low‐Dose Hydrochlorothiazide Alone or in Combination with Quinapril in Black Patients with Mild to Moderate Hypertension , 2000, Journal of clinical pharmacology.
[44] Salim Yusuf,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.
[45] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[46] D. Reda,et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 2000, Archives of internal medicine.
[47] R. Jackson,et al. Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.
[48] M. Metra,et al. A rationale for the use of β-blockers as standard treatment for heart failure , 2000 .
[49] R B D'Agostino,et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. , 2000, American heart journal.
[50] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[51] W. Kannel,et al. Elevated systolic blood pressure as a cardiovascular risk factor. , 2000, The American journal of cardiology.
[52] E. Feskens,et al. The Relation between Blood Pressure and Mortality Due to Coronary Heart Disease among Men in Different Parts of the World , 2000 .
[53] Orton,et al. EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .
[54] M Ishii,et al. [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.
[55] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[56] L. Weinehall,et al. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease? , 1999, Health policy.
[57] Nick Freemantle,et al. β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .
[58] P. Whelton,et al. What is the role of dietary sodium and potassium in hypertension and target organ injury? , 1999, The American journal of the medical sciences.
[59] M. Pfeffer,et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. , 1999, Journal of the American College of Cardiology.
[60] P. Whelton,et al. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. , 1999, Hypertension.
[61] M. Moser. A critique of the world health organization-international society of hypertension guidelines for the management of hypertension , 1999 .
[62] G. Guyatt,et al. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. , 1999, American journal of hypertension.
[63] S. Ebrahim,et al. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. , 1998, Journal of public health medicine.
[64] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[65] N. Nagelkerke,et al. Undertreatment of hypertension in a population‐based study in The Netherlands , 1998, Journal of hypertension.
[66] G. Gamble,et al. Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. , 1998, Journal of hypertension.
[67] Y. Kawano,et al. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. , 1998, Hypertension.
[68] T. Hedner,et al. Survival in treated hypertension: follow up study after two decades , 1998, BMJ.
[69] W L Haskell,et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. , 1998, The New England journal of medicine.
[70] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[71] R. Schmieder,et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[72] G. Assmann,et al. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. , 1998, European heart journal.
[73] J. P. Wilson,et al. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. , 1997, Clinical therapeutics.
[74] Jan A Staessen,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.
[75] J. Avorn,et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. , 1997, American journal of hypertension.
[76] J. Cutler,et al. Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men , 1997, Annals of Internal Medicine.
[77] J. Tuomilehto,et al. Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid? , 1997, Journal of Human Hypertension.
[78] B. Psaty,et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. , 1997, JAMA.
[79] J. Cutler,et al. Randomized trials of sodium reduction: an overview. , 1997, The American journal of clinical nutrition.
[80] E. O’Brien,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.
[81] Pats-Collaborating-Group-. Post-stroke antihypertensive treatment study. A preliminary result , 1995 .
[82] N. Cook,et al. Implications of small reductions in diastolic blood pressure for primary prevention. , 1995, Archives of internal medicine.
[83] J. Oesterling,et al. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. , 1995, The New England journal of medicine.
[84] Pats,et al. Post-stroke antihypertensive treatment study. A preliminary result. , 1995, Chinese medical journal.
[85] J. Manson,et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. , 1994, Archives of internal medicine.
[86] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[87] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[88] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[90] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[91] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[92] P. Byrne. The department of general practice. , 1969, The Manchester medical gazette.